Vermillion Posts $431K in Q1 Revenues | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion said today that its revenues rose to $431,000 in the first quarter, compared to $73,000 in Q1 2010, as more than 3,000 of its OVA1 ovarian cancer tests were performed.

The firm's results fell short of analysts' expectations of $520,000 in revenues.

For the three months ended March 31, product revenues came in at $317,000, compared to none a year ago, and licensing revenues were $114,000, up from $73,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.